Complex effects of naturally occurring mutations in the JAK3 pseudokinase domain: Evidence for interactions between the kinase and pseudokinase domains

Molecular and Cellular Biology

Volumn 20, Issue 3, 2000, Pages 947-956

  Chen, Min ^a,f   Cheng, Alan ^b   Candotti, Fabio ^c   Zhou, Yong Jie ^a   Hymel, Anka ^a   Fasth, Anders ^d   Notarangelo, Luigi D ^e   O'Shea, John J ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF GOTHENBURG   (Sweden)

^e UNIVERSITY OF BRESCIA   (Italy)

^f NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

JANUS KINASE; PHOSPHOTRANSFERASE; PROTEIN TYROSINE KINASE;

ARTICLE; CATALYSIS; CELL TRANSFORMATION; COMBINED IMMUNODEFICIENCY; CONTROLLED STUDY; ENZYME ACTIVITY; EPSTEIN BARR VIRUS; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; PROTEIN STRUCTURE;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANIMALS; B-LYMPHOCYTES; CATALYTIC DOMAIN; CELL LINE, TRANSFORMED; CLONING, MOLECULAR; COS CELLS; HUMANS; INTERLEUKIN-2; JANUS KINASE 3; MUTATION; POINT MUTATION; PROTEIN-TYROSINE KINASES; RECOMBINANT PROTEINS; SEVERE COMBINED IMMUNODEFICIENCY; SIGNAL TRANSDUCTION; TRANSFECTION;

EID: 0033965488     PISSN: 02707306     EISSN: None     Source Type: Journal    
DOI: 10.1128/MCB.20.3.947-956.2000     Document Type: Article

References (47)

1. Boussiotis, V. A., D. L. Barber, T. Nakarai, G. J. Freeman, J. G. Gribben, G. M. Bernstein, A. D. D'Andrea, J. Ritz, and L. M. Nadler. 1994. Prevention of T cell anergy by signaling through the gamma c chain of the IL-2 receptor. Science 266:1039-1042.
2. Cacalano, N. A., T. S. Migone, F. Bazan, E. P. Hanson, M. Chen, F. Candotti, J. J. O'Shea, and J. A. Johnston. 1999. Autosomal SCID caused by a point mutation in the amino-terminus of JAK3: mapping of the JAK3-receptor interaction domain. EMBO J. 18:1549-1558.
3. Candotti, F., J. J. O'Shea, and A. Villa. 1998. Severe combined immune deficiencies due to defects of the common gamma chain-JAK3 signaling pathway. Springer Semin. Immunopathol. 19:401-415.
4. Candotti, F., S. A. Oakes, J. A. Johnston, S. Giliani, R. F. Schumacher, P. Mella, M. Fiorini, A. G. Ugazio, R. Badolato, L. D. Notarangelo, F. Bozzi, P. Macchi, D. Strina, P. Vezzoni, R. M. Blaese, J. J. O'Shea, and A. Villa. 1997. Structural and functional basis for JAK3-deficient severe combined immunodeficiency. Blood 90:3996-4003.
5. Chen, M., A. Cheng, Y. Q. Chen, A. Hymel, E. P. Hanson, L. Kimmel, Y. Minami, T. Taniguchi, P. S. Changelian, and J. J. O'Shea. 1997. The amino terminus of JAK3 is necessary and sufficient for binding to the common gamma chain and confers the ability to transmit interleukin 2-mediated signals. Proc. Natl. Acad. Sci. USA 94:6910-6915.
6. Danial, N. N., A. Pernis, and P. B. Rothman. 1995. Jak-STAT signaling induced by the v-abl oncogene. Science 269:1875-1877.
7. Darnell, J. E. J., I. M. Kerr, and G. R. Stark. 1994 Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 264:1415-1421.
8. Feng, J., B. A. Witthuhn, T. Matsuda, F. Kohlhuber, I. M. Kerr, and J. N. Ihle. 1997. Activation of Jak2 catalytic activity requires phosphorylation of Y1007 in the kinase activation loop. Mol. Cell. Biol. 17:2497-2501.
9. Firmbach-Kraft, I., M. Byers, T. Shows, R. Dalla-Favera, and J. J. Krolewski. 1990. tyk2, prototype of a novel class of non-receptor tyrosine kinase genes. Oncogene 5:1329-1336.
10. Frank, S. J., W. Yi, Y. Zhao, J. F. Goldsmith, G. Gilliland, J. Jiang, I. Sakai, and A. S. Kraft. 1995. Regions of the JAK2 tyrosine kinase required for coupling to the growth hormone receptor. J. Biol. Chem. 279:14776-14785.
11. Fujitani, Y., M. Hibi, T. Fukada, M. Takahashi-Tezuka, H. Yoshida, T. Yamaguchi, K. Sugiyama, Y. Yamanaka, K. Nakajima, and T. Hirano. 1997. An alternative pathway for STAT activation that is mediated by the direct interaction between JAK and STAT. Oncogene 14:751-761.
12. Gauzzi, M. C., L. Velazquez, R. McKendry, K. E. Mogensen, M. Fellous, and S. Pellegrini. 1996. Interferon-alpha-dependent activation of Tyk2 requires phosphorytation of positive regulatory tyrosines by another kinase. J. Biol. Chem. 271:20494-20500.
13. Gurniak, C. B., and L. J. Berg. 1996. Murine JAK3 is preferentially expressed in hematopoietic tissues and lymphocyte precursor cells. Blood 87: 3151-3160.
14. Harpur, A.G., A.C. Andres, A. Ziemiecki, R. R. Aston, and A. F. Wilks. 1992. JAK2, a third member of the JAK family of protein tyrosine kinases. Oncogene 7:1347-1353.
15. Hou, J., U. Schindler, W. J. Henzel, S. C. Wong, and S. L. McKnight. 1995. Identification and purification of human Stat proteins activated in response to interleukin-2. Immunity 2:321-329.
16. Hubbard, S. R., M. Mohammadi, and J. Schlessinger. 1998. Autoregulatory mechanisms in protein-tyrosine kinases. J. Biol. Chem. 273:11987-11990.
17. Ihle, J. N., B. A. Witthuhn, F. W. Quelle, K. Yamamoto, and O. Silvennoinen. 1995. Signaling through the hematopoietic cytokine receptors. Annu. Rev. Immunol. 13:369-398.
18. Johnston, J. A., C. M. Bacon, D. S. Finbloom, R. C. Rees, D. Kaplan, K. Shibuya, J. R. Ortaldo, S. Gupta, Y. Q. Chen, J. D. Giri, and J. J. O'Shea. 1995. Tyrosine phosphorylation and activation of STAT5, STAT3, and Janus kinases by interleukins 2 and 15. Proc. Natl. Acad. Sci. USA 92:8705-8709.
19. Johnston, J. A., M. Kawamura, R. A. Kirken, Y. Q. Chen, T. B. Blake, K. Shibuya, J. R. Ortaldo, D. W. McVicar, and J. J. O'Shea. 1994. Phosphorylation and activation of the Jak-3 Janus kinase in response to interleukin-2. Nature 370:151-153.
20. Kawamura, M., D. W. McVicar, J. A. Johnston, T. B. Blake, Y. Q. Chen, B. K. Lal, A. R. Lloyd, D. J. Kelvin, J. E. Staples, J. R. Ortaldo, and J. J. O'Shea. 1994. Molecular cloning of L-JAK, a Janus family protein-tyrosine kinase expressed in natural killer cells and activated leukocytes. Proc. Natl. Acad. Sci. USA 91:6374-6378.
21. Lacronique, V., A. Boureux, V. D. Valle, H. Poirel, C. T. Quang, M. Mauchauffe, C. Berthou, M. Lessard, R. Berger, J. Ghysdael, and O. A. Bernard. 1997. A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia. Science 278:1309-1312.
22. Leonard, W. J. 1996. Dysfunctional cytokine receptor signaling in severe combined immunodeficiency. J. Investig. Med. 44:304-311.
23. Leonard, W. J. 1999. Type I cytokines and interferons, p. 741-774. In W. E. Paul (ed.), Fundamental immunology, 4th ed. Lippincott-Raven Publishers, Philadelphia, Pa.
24. Lin, J. X., T. S. Migone, M. Tsang, M. Friedmann, J. A. Weatherbee, L. Zhou, A. Yamauchi, E. T. Bloom, J. Mietz, S. John, and W. J. Leonard. 1995. The role of shared receptor motifs and common Stat proteins in the generation of cytokine pleiotropy and redundancy by IL-2, IL-4, IL-7, IL-13, and IL-15. Immunity 2:331-339.
25. Liu, K. D., S. L. Gaffen, M. A. Goldsmith, and W. C. Greene. 1997. Janus kinases in interleukin-2-mediated signaling: JAK1 and JAK3 are differentially regulated by tyrosine phosphorylation. Curr. Biol. 7:817-826.
26. Luo, H., P. Rose, D. Barber, W. P. Hanratty, S. Lee, T. M. Roberts, A. D. D'Andrea, and C. R. Dearolf. 1997. Mutation in the Jak kinase JH2 domain hyperactivates Drosophila and mammalian Jak-Stat pathways. Mol. Cell. Biol. 17:1562-1571.
27. Macchi, P., A. Villa, S. Gillani, M. G. Sacco, A. Frattini, F. Porta, A. G. Ugazio, J. A. Johnston, F. Candotti, J. J. O'Shea, P. Vezzoni, and L. D. Notarangelo. 1995. Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID). Nature 377:65-68.
28. Meydan, N., T. Grunberger, H. Dadi, M. Shahar, E. Arpaia, Z. Lapidot, J. S. Leeder, M. Freedman, A. Cohen, A. Gazit, A. Levitzki, and C. M. Roifman. 1996. Inhibition of acute lymphohlastic leukaemia by a Jak-2 inhibitor. Nature 379:645-648.
29. Migone, T. S., J. X. Lin, A. Cereseto, J. C. Mulloy, J. J. O'Shea, G. Franchini, and W. J. Leonard. 1995. Constitutively activated Jak-STAT pathway in T cells transformed with HTLV-1. Science 269:79-81.
30. Minami, Y., I. Oishi, Z. J. Liu, S. Nakagawa, T. Miyazaki, and T. Taniguchi. 1994. Signal transduction mediated by the reconstituted IL-2 receptor. Evidence for a cell type-specific function of IL-2 receptor beta-chain. J. Immunol. 152:5680-5690.
31. Miyazaki, T., A. Kawahara, H. Fujii, Y. Nakagawa, Y. Minami, Z. J. Liu, I. Oishi, O. Silvennoinen, B. A. Witthuhn, J. N. Ihle, and T. Tanaguchi. 1994. Functional activation of Jak1 and Jak3 by selective association with IL-2 receptor subunits. Science 266:1045-1047.
32. Morelon, E., A. Dautry-Varsat, F. Le Deist, S. Hacein-Bay, A. Fischer, and G. de Saint Basile. 1996. T-lymphocyte differentiation and proliferation in the absence of the cytoplasmic tail of the common cytokine receptor gamma c chain in a severe combined immune deficiency X1 patient. Blood 88:1708-1717.
33. Noguchi, M., H. Yi, H. M. Rosenblatt, A. H. Filipovich, S. Adelstein, W. S. Modi, O. W. McBride, and W. J. Leonard. 1993. Interleukin-2 receptor gamma chain mutation results in X-linked severe combined immunodeficiency in humans. Cell 73:147-157.
34. Nosaka, T., J. M. van Deursen, R. A. Tripp, W. E. Thierfelder, B. A. Witthuhn, A. P. McMickle, P. C. Doherty, G. C. Grosveld, and J. N. Ihle. 1995. Defective lymphoid development in mice lacking Jak3. Science 270:800-502.
35. O'Shea, J. J., and W. J. Leonard. 1998. Jaks and STATs: biological implications. Annu. Rev. Immunol. 16:293-322.
36. Park, S. Y., K. Saijo, T. Takahashi, M. Osawa, H. Arase, N. Hirayama, K. Miyake, H. Nakauchi, T. Shirasawa, and T. Saito. 1995. Developmental defects of lymphoid cells in Jak3 kinase-deficient mice. Immunity 3:771-782.
37. Russell, S. M., J. A. Johnston, M. Noguchi, M. Kawamura, C. M. Bacon, M. Friedmann, M. Berg, D. W. McVicar, B. A. Witthuhn, O. Silvennoinen, A. S. Goldman, F. C. Schmalsteig, J. N. Ihle, J. J. O'Shea, and W. J. Leonard. 1994. Interaction of IL-2R beta and gamma c chains with Jak1 and Jak3: implications for XSCID and XCID. Science 266:1042-1045.
38. Russell, S. M., N. Tayebi, H. Nakajima, M. C. Riedy, J. L. Roberts, M. J. Aman, T. S. Migone, M. Noguchi, M. L. Markert, R. H. Buckley, J. J. O'Shea, and W. J. Leonard. 1995. Mutation of Jak3 in a patient with SCID: essential role of Jak3 in lymphoid development. Science 270:797-800.
39. Sakai, I., and A. S. Kraft. 1997. The kinase domain of Jak2 mediates induction of bcl-2 and delays cell death in hematopoietic cells. J. Biol. Chem. 272:12350-12358.
40. Schmalstieg, F. C., W. J. Leonard, M. Noguchi, M. Berg, H. E. Rudloff, R. M. Denney, S. K. Dave, E. G. Brooks, and A. S. Goldman. 1995. Missense mutation in exon 7 of the common gamma chain gene causes a moderate form of X-linked combined immunodeficiency. J. Clin. Investig. 95:1169-1173.
41. Thomis, D. C., C. B. Gurniak, E. Tivol, A. H. Sharpe, and L. J. Berg. 1995. Defects in B lymphocyte maturation and T lymphocyte activation in mice lacking Jak3. Science 270:794-797.
42. Velazquez, L., K. E. Mogensen, G. Barbieri, M. Fellous, G. Uze, and S. Pellegrini. 1995. Distinct domains of the protein tyrosine kinase tyk2 required for binding of interferon-alpha/beta and for signal transduction. J. Biol. Chem. 270:3327-3334.
43. Waldmann, T. A., and J. J. O'Shea. 1998. The use of antibodies against the IL-2 receptor in transplantation. Curr. Opin. Immunol. 10:507-512.
44. Wilks, A. F., A. G. Harpur, R. R. Kurban, S. J. Ralph, G. Zurcher, and A. Ziemiecki. 1991. Two novel protein-tyrosine kinases, each with a second phosphotransferase-related catalytic domain, define a new class of protein kinase. Mol. Cell. Biol. 11:2057-2065.
45. Witthuhn, B. A., O. Silvennoinen, O. Miura, K. S. Lai, C. Cwik, E. T. Liu, and J. N. Ihle. 1994. Involvement of the Jak-3 Janus kinase in signalling by interleukins 2 and 4 in lymphoid and myeloid cells. Nature 370:153-157.
46. Xu, W., S. C. Harrison, and M. J. Eck. 1997. Three-dimensional structure of the tyrosine kinase c-Src. Nature 385:595-602.
47. Zhou, Y. J., E. P. Hanson, Y. Q. Chen, K. Magnuson, M. Chen, P. G. Swann, R. L. Wange, P. S. Changelian, and J. J. O'Shea. 1997. Distinct tyrosine phosphorylation sites in JAK3 kinase domain positively and negatively regulate its enzymatic activity. Proc. Natl. Acad. Sci. USA 94:13850-13855.